Zymeworks (ZYME) Stock Price, News & Analysis

Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Key Stats

• Today's Range: $11.96 to $12.70
• 50-Day Range: $9.44 to $13.05
• 52-Week Range: $8.21 to $17.70
• Volume: 606,940 shs
• Average Volume: 597,595 shs
• Market Capitalization: $864.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Moderate Buy

Zymeworks Stock Analysis - MarketRank™

Zymeworks scored higher than 72% of companies evaluated by MarketBeat, and ranked 270th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Zymeworks has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Zymeworks are expected to decrease in the coming year, from ($1.39) to ($1.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zymeworks is -8.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zymeworks is -8.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zymeworks has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ZYME.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zymeworks does not currently pay a dividend.

Dividend Growth

Zymeworks does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ZYME.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.21

News Sentiment

Zymeworks has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Zymeworks this week, compared to 5 articles on an average week.

Search Interest

4 people have searched for ZYME on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Zymeworks insiders have bought more of their company's stock than they have sold. Specifically, they have bought $16,773,032.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.92% of the stock of Zymeworks is held by insiders.

Percentage Held by Institutions

92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ZYME Stock Analysis - Frequently Asked Questions

How have ZYME shares performed this year?

Zymeworks' stock was trading at $14.64 at the beginning of 2025. Since then, ZYME shares have decreased by 15.1% and is now trading at $12.43.
View the best growth stocks for 2025 here.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. The company's revenue for the quarter was up 170.3% on a year-over-year basis.

When did Zymeworks IPO?

Zymeworks (ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Who are Zymeworks' major shareholders?

Zymeworks' top institutional shareholders include EcoR1 Capital LLC (24.81%), Redmile Group LLC (6.88%), UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (5.58%) and Vanguard Group Inc. (2.54%). Insiders that own company stock include Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Paul Andrew Moore, Neil Josephson, Jeffrey T L Smith and Christopher Astle.
View institutional ownership trends.

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zymeworks investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/21/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ZYME
• Previous Symbol: NASDAQ:ZYME
• CIK: 1937653
• Web: www.zymeworks.com
• Phone: (302) 274-8744
• Fax: 604-737-7077
• Employees: 460
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $30.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +68.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-118,670,000.00
• Net Margins: -182.75%
• Pretax Margin: -189.75%
• Return on Equity: -23.00%
• Return on Assets: -18.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.10
• Quick Ratio: 4.10

Sales & Book Value

• Annual Sales: $93.38 million
• Price / Sales: 9.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.63 per share
• Price / Book: 1.87

Miscellaneous

• Outstanding Shares: 69,577,000
• Free Float: 67,556,000
• Market Cap: $864.84 million
• Optionable: Optionable
• Beta: 1.24